CAPR Profile
Capricor Therapeutics, Inc., based in San Diego, California, is a clinical-stage biotechnology company dedicated to developing innovative cell and exosome-based therapeutics aimed at treating a broad spectrum of diseases and disorders. Founded in 2005, Capricor is at the forefront of harnessing advanced cellular technologies to address significant unmet medical needs.
The company's lead therapeutic candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy currently in Phase III clinical trials for late-stage Duchenne muscular dystrophy (DMD). This innovative therapy is designed to target the underlying muscle degeneration associated with DMD, offering new hope for patients with this severe genetic condition. Additionally, CAP-1002 is being evaluated in Phase II trials for its potential to treat cytokine storm associated with SARS-CoV-2, highlighting its versatility in addressing severe inflammatory responses.
Capricor is also advancing CAP-2003, which is in pre-clinical development for treating trauma-related injuries and conditions. This program aims to leverage cellular therapies to promote tissue repair and recovery in severe injury contexts. Furthermore, the company is developing two vaccine candidates focused on preventing COVID-19, reflecting its commitment to addressing global health challenges through innovative solutions.
To support its clinical programs, Capricor collaborates with Lonza Houston, Inc. for the manufacturing of CAP-1002, ensuring the production of high-quality cell therapy products. The company's ongoing research and development efforts underscore its dedication to pioneering cell-based treatments and vaccines that could transform patient care across a range of serious health conditions.
|
